A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Inclusion Criteria:

• The participant could, in the opinion of the Investigator, benefit from long-termdapirolizumab pegol (DZP) treatment

• The participant completed one of the parent studies within 4 weeks prior to entry tothis study

Exclusion Criteria:

• Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study